drugset / Trial / NCT02319057

Pharmacokinetic Study of Single Doses of ORM-12741

NCT02319057 ↗

Phase 1 Completed 23 enrolled Orion Corporation, Orion Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate ORM-12741 concentrations in the blood after different study drug formulations

Timeline

Start
2014-09
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ORM-12741 Small molecule — Oral

Indications

No indication recorded.